P D F - S E A R C H

Found 809 answers for 'Ecallantide'.

Kalbitor (ecallantide)
Requests for Kalbitor (ecallantide) may be approved for individuals who meet the following criteria: I. Individual is 12 years of age or older; AND II. Individual is using Kalbitor for the treatment of acute...


Overview of ecallantide in the treatment of
Introduction to ecallantide Ecallantide is a potent and specific plasma kallikrein inhibitor that blocks generation of bradykinin. Pharmacodynamics Ecallantide delays thrombin generation in vitro [25].


Ecallantide for the treatment of acute attacks of hereditary
Ecallantide is a highly specific and potent plasma kallikrein inhibitor approved for the treatment of acute attacks of HAE-C1INH. In two randomized, placebo-controlled, Phase III clinical trials...


Update on recent trials in the treatment of
Ecallantide-treated patients reported a significant decrease from baseline MSCS score as compared with placebo. Ecallantide represents a novel treatment option for patients with HAE [27].


Ecallantide. This information from Lexicomp® explains what you need to know about this Ecallantide. 5/7. This information should not be used to decide whether or not to take this medicine or...


Ecallantide. Brand Names: US. Warning. General drug facts. Ecallantide. 3/5. If your symptoms or health problems do not g et better or if they become worse, call your doctor.


Kalbitor® (ecallantide)
KALBITOR® (ecallantide) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval. ©2018, Magellan Rx Management.


KALBITOR- ecallantide injection, s olution
KALBITOR (ecallantide) is a human plasma kallikrein inhibitor for injection for subcutaneous use. ecallantide. 10 mg/mL Injection For Subcutaneous Use Only Single Use; Discard Unused Portion Net...


Clinical Policy: Ecallantide (Kalbitor)
Description Ecallantide (Kalbitor®) is a plasma kallikrein inhibitor. FDA Approved Indication(s) Kalbitor is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age...


Kalbitor ® (ecallantide)
(ecallantide). When requesting Kalbitor® (ecallantide), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and...